Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303847 | 0.85 | EPHX1 (0.53) | EPHX1 | |
| SCHEMBL342676 | 0.85 | — | — | |
| SCHEMBL24758165 | 0.84 | EPHX1 (0.39) | EPHX1 | |
| Ammonia Solution, Strong SCHEMBL2286653 | 0.82 | — | — | |
| SCHEMBL26117100 | 0.79 | — | — | |
| Alcohol SCHEMBL3149030 | 0.79 | — | — | |
| Lithium Ion SCHEMBL26117105 | 0.77 | — | — | |
| SCHEMBL16359606 | 0.77 | EPHX1 (0.46) | EPHX1 | |
| SCHEMBL16094027 | 0.77 | EPHX1 (0.46) | EPHX1 | |
| SCHEMBL16119813 | 0.74 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4634159-A1 | SULFOXIMINES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4611747-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | Genep Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3873467-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| WO-2024126648-A1 | SULFOXIMINES AS INHIBITORS OF NaV1.8 | Grünenthal GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024097171-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | GENEP INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11970479-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20210395224-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395224-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| CN-104718188-B | The benzamides of N- substitutions and its purposes in treating pain | 基因泰克公司 | 2018-08-21 | — | — | CN | disclosed |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2855428-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | Genentech, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177224-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | GENENTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970479-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM3, CHRM1 | EPHX1 1089/4885APLNR 367/4885 |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | EPHX1 2071/4885APLNR 2987/4885 |
| US-20130317001-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | EPHX1 2071/4885APLNR 2987/4885 |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | EPHX1 2028/4885APLNR 1164/4885 |
| US-20210395224-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM4, CHRM3, CHRM1 | EPHX1 1089/4885APLNR 367/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | EPHX1 3727/4885APLNR 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.